HirshJ, WarkentinTE, ShaughnessySG. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest2001;119(1 suppl):64S–94S.
2.
BuckleyMM, SorkinEM. Enoxaparin. A review of its pharmacology and clinical application in the prevention and treatment of thromboembolic disorders. Drugs1992;44:465–97.
LevineMN, PlanesA, HirshJ, GoodyearM, VochelleN, GentM.The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost1989;62:940–4.
5.
NaranjoCA, BustoU, SellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;30:239–45.
